Systematic review of cardiac adverse effects in children and young people under 18 years of age after SARS-CoV-2 vaccination

Joana Cruz¹

Amedine Duret²

Rachel Harwood^{3 4}

Lorna K. Fraser⁵

Caroline B. Jones⁶

Joseph Ward¹

Elizabeth Whittaker^{2 7}

Simon E. Kenny^{2 7 8}

Russell M. Viner¹

¹ Population, Policy and Practice Department, UCL Great Ormond St. Institute of Child Health, London, UK

² Department of Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, UK

³ Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK

⁴ Department of Paediatric Surgery, Alder Hey Children's Hospital, Liverpool, UK

⁵ Martin House Research Centre, University of York, York, UK

⁶ Alder Hey Children's Hospital, Liverpool, UK

⁷ Section of Paediatric Infectious Diseases, Faculty of Medicine, Imperial College London, London, UK

⁸ NHS England and NHS Improvement, London, UK

27 Abstract

28 Background

29 Reports of myocarditis and pericarditis following vaccination with mRNA vaccines for SARS-
30 CoV-2 have occurred after countries began vaccinating adolescents. We undertook a sys-
31 tematic review of cardiac adverse effects associated with SARS-CoV-2 vaccine in children
32 and young people (CYP) < 18 years.

33 Methods

34 Systematic review with protocol prospectively registered with PROSPERO
35 (CRD42021275380).

36 Six electronic databases were searched from 1 December 2019 to 14 September 2021. Eligi-
37 ble studies were those reporting on CYP with reported or proven myocarditis, pericarditis
38 and/or myopericarditis associated with vaccination against SARS-CoV-2. We summarized
39 findings across all clinical cases reported in case report / case series studies. As a number of
40 studies reported data from two publicly available vaccine surveillance systems, we updated
41 estimates of reporting rates for cardiac adverse events up to 31 October for the US Vaccine
42 Adverse Event Reporting System (VAERS) and 13 November for EudraVigilance covering Eu-
43 ropean Union and European Economic Area (EUEA) countries.

44 Results

45 Twenty-one studies were included from 338 identified records. Seventeen were case re-
46 ports/series describing a total of 127 CYP. Three studies described reporting rates from pas-
47 sive surveillance databases (VAERS, EudraVigilance, and the WHO VigiBase) and one de-
48 scribed 22 cases from the US Vaccine Safety Datalink (VSD).

49 Clinical series reported that 99.2% presented with chest pain, 100% had raised troponin and
50 73.8% had an abnormal ECG. Cardiovascular magnetic resonance (CMR) in 91 cases identi-
51 fied myocardial injury in 61.5%, with 90.1% showing late gadolinium enhancement. NSAIDs
52 were the most common treatment (76.0%).

53 One US dataset (VSD) estimated a significant excess of 29.6 events per million vaccine doses
54 across both sexes and doses. There were 1129 reports of myocarditis and 358 reports of
55 pericarditis from across the USA and EU/EEA. The VAERS reporting rate per million for myo-
56 carditis was 12.4 for boys and 1.4 for girls after the first dose, and 49.6 for boys and 6.1 for
57 girls after the second dose. There was a marked trend for VAERS reporting to be highest
58 soon after initiation of the vaccine schedule, suggesting reporting bias.

59 Conclusions

60 Cardiac adverse effects are very rare after mRNA vaccination for COVID-19 in CYP <18 years.
61 The great majority of cases are mild and self-limiting without significant treatment. No data
62 are yet available on children under 12 years. Larger detailed longitudinal studies are ur-
63 gently needed from active surveillance sources.

64

65 Introduction

66 The introduction of vaccines to protect against serious illness in SARS-Cov-2 has been highly
 67 effective ¹. However, there have been a number of case reports describing cardiac adverse
 68 effects, namely myocarditis, pericarditis and myopericarditis after SARS-CoV-2 vaccination ²
 69 ³. From May 2021 onward, several countries extended vaccination to include children and
 70 young people (CYP) aged 12-15 years old ^{4 5}. Soon after this, reports were published of cases
 71 of myocarditis in CYP after SARS-CoV-2 vaccination, especially in males ⁶. Myocarditis and
 72 associated conditions have also been reported after SARS-CoV-2 infection, both with COVID-
 73 19 disease ⁷⁻⁹ and with the post-infectious paediatric multisystem inflammatory syndrome
 74 (PIMS) ¹⁰, also known as multisystem inflammatory syndrome in children (MIS-C).

75 By October 2021, several reports had been published with wide variation in reported fre-
 76 quency of myocarditis after vaccination ^{9 11 12}. The frequency of myocarditis in these studies
 77 varied according to gender, age group and whether first or second dose administered ^{13 14}.

78 Estimates across broader age-groups using high-quality data sources suggest the risk of my-
 79 ocarditis was highest amongst young men, with estimated incidence after the first dose of
 80 106.9 per million amongst males 16-29 years, ¹¹ and 13.4 and 150.7 per million after first and
 81 second doses respectively. ¹² Males aged 12-15 years old appeared most affected, particu-
 82 larly after the second dose. ^{13 14}

83 As of early November 2021, over 50 million doses of mRNA vaccines have been given to 12-
 84 17 year olds across the USA ¹⁵ and European Union and European Economic Area ¹⁶ countries,
 85 with an additional 2.8 million doses given in the UK ¹⁷ and 3.1 million in Australia. ¹⁸

86 Establishing the nature and frequency of vaccination adverse events such as myocarditis is
 87 essential to inform both national vaccination strategies and clinical decision-making for indi-
 88 viduals, particularly as nations expand adolescent vaccination and consider vaccinating
 89 younger children. We therefore undertook a systematic review of cardiac adverse effects
 90 associated with SARS-CoV-2 vaccine in those under 18 years.

91

92 Methods

93 We followed a standardised methodology and reported results according to Preferred Re-
 94 porting Items for Systematic Reviews and Meta-Analyses (PRISMA) ¹⁹ recommendations.
 95 The protocol was prospectively registered with PROSPERO (CRD42021275380).

96 Review question

97 What are the characteristics, frequency and natural history of cardiac adverse effects in chil-
 98 dren and young people (CYP) (<18 years old) after SARS-CoV-2 immunisation?

99 Search strategy

100 We systematically searched PubMed, MedRxiv, Europe PMC, World Health Organisation's
 101 COVID-19 Global Literature on Coronavirus Disease, Research Square and Google Scholar

from 1 December 2019 to 14 September 2021 for peer-reviewed papers and reports on cardiac adverse events caused by SARS-CoV-2 immunisation in CYP. The search strategy used the keywords “myocarditis” OR “pericarditis” OR “adverse effects” AND “covid-19” AND “vaccin*” AND “children” OR “adolescent” OR “paediatric” in title or abstract of the reference. The complete list of key word strings for each database can be found in supplementary appendix (Table S1). The first 40 results from Google Scholar were also analysed, along with the databases of the US Vaccine Adverse Event Reporting System (VAERS)²⁰ and EudraVigilance—the European database of suspected adverse drug reaction reports²¹ for cases of myocarditis, pericarditis or myopericarditis related with SARS-CoV-2 vaccine in CYP aged between 12-17 years old. We included adverse effects from mRNA-1273 (Moderna) and BNT 162b2 (Pfizer) vaccines since they were the only vaccines approved for the age group <18 years old at the time of writing of this paper.

Eligibility

We included papers that reported myocarditis, pericarditis and/or myopericarditis associated with vaccination against SARS-CoV-2 in CYP, aged <18 years old. Studies that also included individuals older than 18 years old were included if they allowed extraction of data on eligible individuals and/or age groups separately. We excluded studies on CYP SARS-CoV-2 vaccination trials (being underpowered), systematic reviews that mentioned cardiovascular involvement but did not specify the above conditions, studies that included patients with cardiovascular conditions diagnosed prior to SARS-CoV-2 vaccination or that used non-human models. Where multiple studies reported data from vaccine surveillance databases, we included only the most recent studies to avoid duplication.

Study selection

The PRISMA flowchart is shown in figure 1. Our search identified 330 articles to which we added eight articles identified through the snowball technique. Titles and abstracts of potentially eligible articles and full-text review were scrutinised by one investigator (JC). Of those, 271 were ineligible based on criteria and 46 articles were excluded as duplicates, with 21 articles included in this review.

Data extraction

The following information was extracted from included studies: author and year of publication, type of study (cohort, case report or case series), number of cases, case source, patients’ sex, median age and range, vaccine type, percentage of patients presenting symptoms after second vaccination, percentage of patients with symptoms resolved, median and range hospitalisation days and diagnoses of cardiac adverse effects. For the diagnostic criteria and treatment, we extracted the patients’ symptoms, troponin and c-reactive protein blood serum concentration, and observations from electrocardiogram, echocardiogram and cardiovascular magnetic resonance, as well as treatment provided. These data were extracted to a spreadsheet by one reviewer (JC) and checked by two reviewers (JW, AD). They reached agreement regarding any conflicting results.

Quality evaluation

Quality evaluation of case reports/case series was assessed using the case-report (CARE) 13-item guideline²². This guideline comprises 30 sub-items. Each item ratings are 'yes' or 'no', and the final quality evaluation score was the sum of sub-items. The quality evaluation was performed independently by two reviewers (JC and AD) and in case of disagreement, a third reviewer (LF) made the final decision. Quality evaluation for each case report/case series are available in supplementary material (Table S2).

Data synthesis

We considered data from case reports/case series separately from the data extracted from databases reporting adverse effects of vaccination against SARS-CoV-2. Data from three passive surveillance databases were used in included studies; the European Medicines Agency's European database of suspected adverse drug reaction reports (EudraVigilance, covering European Union and European Economic Area countries)²¹, the Centers for Disease Control (CDC) Vaccine Adverse Event Reporting System (VAERS, covering the USA),²⁰ and the World Health Organisation's global Individual Case Safety Report Database, VigiBase²³. More than 130 countries contribute to VigiBase although more than 85% of adverse effects caused by BNT162b2 (Pfizer) vaccine were reported from countries in Europe and America²⁴. As above, we only included the most recent studies from these databases. Data were available from one active surveillance system, the CDC's Vaccine Safety Datalink (VSD)²⁵ which is a collaboration between the CDC and eight managed care organisations covering 3.6% of the US population. Participating VSD sites file weekly reports of medically-attended (clinic, emergency department or hospital) adverse events of COVID-19 vaccination for total 10.2 million participants aged ≥ 12 years.

Additional data

We additionally updated estimates from EudraVigilance²¹ and VAERS²⁰. We calculated crude reporting rates for cardiac adverse events per million doses administered used the denominator being the sum of first dose and all fully vaccinated CYP as of 6 November 2021 for European Union and European Economic Area countries¹⁶ and 31 October 2021 for the USA.¹⁵ For the USA, but not EU countries, we were also able to stratify adverse effects and calculate crude rates by sex and by dose, using data on proportional US adolescent vaccine uptake by sex following previous reports.²⁶ For EU/EEA countries, we considered a time lag of 7-days to consider both reporting lag and a pre-defined 7-day risk window, following previous reports¹⁴; for USA VAERS, we used the vaccination month reported. For this dataset, we were able to repeat these analyses by month of vaccination from December 2020 to October 2021.

Results

Our review included 21 articles^{14 23 27-44} together with updated data from EudraVigilance²¹ and VAERS²⁰.

Case series/case reports

Seventeen articles were case reports or series that described between one^{31 34 35 40} and 31³² patients aged <18 years, with a total sample of 127 (see Table 1). Most were from the USA (82%)^{28-30 32-38 40-43}, with 2 from Israel^{27 39} and 1 from Germany³¹. 92.1% of cases were male and the median age ranged between 15 and 17 years. Sixteen described occurrence of cardiac adverse events after vaccination with BNT162b2 (Pfizer) vaccine and one study included cases after Pfizer or Moderna (mRNA-1273) vaccines³². Events were observed after administration of second dose (92.1%) with onset symptoms within 2^{27 28 32 33 39 41-43} and 4.5³⁰ days (median).

Sixty-four patients had myocarditis^{27 29 31-33 35 36 38 40 42 43} and 56 myopericarditis.^{28 30 34 37 39 41} A further 14 patients aged 12-20 years in one study³² were considered to have clinically suspected myocarditis although the number 12-17 years was not specified. No patients 0-17 years died of cardiac adverse effects after vaccination in any study. Where reported, the median hospitalisation days ranged between 2^{29 37 41} and 7³¹ days, and all made full clinical recovery^{28 30-37 39 42 43} except 14 patients^{29 33 42}. In the latter cases, at the time of discharge, three patients had mildly elevated troponin levels, one had persistent borderline low left ventricular systolic function on echocardiogram (EF 54%) and another had non-sustained ventricular tachycardia.²⁹ Three patients had abnormal cardiovascular magnetic resonance (CMR) results with late gadolinium enhancement (LGE).²⁹ Six patients' ECGs, at follow-up, revealed persistent changes, either nonspecific T-wave changes^{33 29}, T-wave inversion²⁹ or a repolarisation abnormality.⁴² Clinical and laboratory findings and treatment given are summarized across the 17 case studies/series in Table 2. Presentation was most commonly with acute chest pain followed by fever and shortness of breath (Table 2). All patients had an elevated troponin (more significant in those with myocarditis) and most a raised CRP. 73.8% of patients had an abnormal ECG at presentation, typically with ST elevation or diffuse ST changes in addition to T wave inversion. Echocardiographic assessment showed normal left ventricular wall geometry and preserved systolic function in the majority. CMR imaging was undertaken in 91 cases with findings suggesting myocardial injury including 56 (61.5%) with myocardial oedema and 82 (90.1%) with LGE. Systolic or diastolic dysfunction was only evident in 5.6% and 7.7%, by echo or CMR assessment, respectively, and 11.3% and 20.9% of patients were noted to have pericardial effusion also by echo or CMR assessment.

Treatment most commonly used nonsteroidal anti-inflammatory agents (NSAIDs; 76.0%). Small numbers (14.9%) were treated with corticosteroids. Immunomodulatory therapy in the form of IVIG was used in 19.8% as treatment for myocarditis. Small numbers received diuretics or angiotensin-converting enzyme (ACE) inhibitors (Enalapril; 1.7%) to treat left ventricular systolic dysfunction, or colchicine (2.5%) to prevent recurrent pericarditis. No patients required inotropic or mechanical support. Two (1.7%) patients required no treatment.

SARS-CoV-2 vaccination adverse effects reported from databases – systematic review

Three included studies used data extracted from passive vaccine surveillance systems, the EudraVigilance⁴⁴, VAERS^{20 44} and VigiBase²³ databases with most recent data being from 30 June 2021 (VigiBase²³), 6 August 2021 (EudraVigilance⁴⁴) and 18 August 2021 (VAERS²⁰).

We included also a study using Vaccine Safety Database (VSD) data, which included three reports.⁴⁵⁻⁴⁷

VAERS data on reported cases of myocarditis per million amongst US 12-15 year old boys were 4.8 and 42.6 for first and second dose of the Pfizer vaccine¹⁴. For girls of the same age group, the cases of myocarditis were 0.5 and 4.3 per million of per million of first and second dose of Pfizer vaccine, respectively¹⁴. For age group 16-17, the number of cases increased. After the first dose, there were 5.2 and 0.0 cases of myocarditis per million of Pfizer vaccine administered, in boys and girls respectively¹⁴. After the second dose, the numbers increased to 71.5 and 8.1 cases per million of Pfizer vaccine administered, respectively¹⁴. Cases of myocarditis after administration of Moderna vaccine were only reported in boys aged 16-17; after the second dose, 31.2 cases per million of Moderna vaccine administered.¹⁴

Only one study published data extracted from EudraVigilance, reporting 61 cases of myocarditis and 14 of pericarditis, in CYP aged 12-17 years, after at least one dose of Pfizer or Moderna vaccines, by 6 August 2021⁴⁴. These adverse cardiac effects affected mostly boys (myocarditis: 87%; pericarditis: 64.3%) and were predominantly after Pfizer vaccine (myocarditis: 98.3%; pericarditis: 100%) rather than Moderna vaccines⁴⁴. Relationship to dose-number and frequency of events per million doses were not available for 12-17 year olds. Whilst some deaths were reported post-vaccine across all ages, data were not available to identify whether within the CYP age-range.

The study from VigiBase reported 291 events after the Pfizer vaccine and 3 after the Moderna vaccine; 249 events were myocarditis and 45 were pericarditis, with no deaths amongst the 12-17 year age-group²³. Compared with females, the odds of myocarditis was 12.0 (95% CI: 7.9-18.3) for males 12-17 years, with odds for pericarditis amongst boys compared with girls being 12.7 (95% CI: 4.5-35.5)²³.

The study using VSD data (3 reports)⁴⁵⁻⁴⁷ identified 22 events in the 21 days after SARS-CoV-2 vaccination amongst US 12-17 year olds in data from December 2020 to 21 August 2021. These were a subgroup of a larger sample of 100 cases amongst 12-39 year olds of which 78 (78%) were considered to be true cases of myo- or pericarditis after expert review. Amongst the 22 proven cases in 12-17 year olds, 50% (n=11) had acute myocarditis, 45% (10) myopericarditis and 5% (1) had acute pericarditis. All (22) presented with chest pain and 64% (14) had shortness of breath. 95% (21) had elevated troponin, 73% (16) had an abnormal ECG and 43% (9/21) had an abnormal echocardiogram. 82% (18) were male with a median onset of symptoms of 2 days. 86% (19) were hospitalised (32% (7) to intensive care) and all were discharged home, with 59% discharged within 2 days.⁴⁵ Using additional data to 10 September 2021⁴⁶ on 12-17 year olds, they estimated that for the Pfizer vaccine only (30 confirmed events), there was a significant excess of 29.6 events per million vaccine doses across both sexes and doses, when compared with vaccinated adolescents 22-42 days after each dose, adjusted for site, sex, ethnicity and date. Estimates were 3.8 per million for first doses (not significantly different to zero) and 56.7 per million (significantly different to zero, confidence intervals not reported) for second doses. Three-month follow-up data were available on 16

of the cohort after Pfizer-BioNTech vaccination, of whom 4 (25%) were still symptomatic and 2 (13%) remained on medication, although no data were available on a control group.

Updated data on SARS-CoV-2 vaccination adverse effects from VAERS and EudraVigilance
We updated the data on cardiac events post vaccination amongst 0-17 year olds in VAERS and EudraVigilance to the latest available data at the time of writing (17 November 2021) (Table 3; Figure 2).

In the USA, 406 cases of myocarditis and 120 of pericarditis were reported to VAERS²⁰ by 31 October 2021. In the EU/EEA, 723 cases of myocarditis and 238 of pericarditis were reported by 13 November 2021 (Table 3). Total number of cardiac events were not calculated due to potential duplicate reporting across these categories.

Two reports recorded death after Pfizer vaccination. One from VAERS was a 15 year old male who died of drowning five days after his second vaccine dose. Autopsy identified increased left ventricular wall thickness and a small focus of myocardial inflammation but a normal pericardium. Genetic analysis of 92 genes associated with inherited cardiomyopathies and arrhythmias identified two variants of unknown significance. The second, from EudraVigilance, was a health professional report of the death of a 12-17 year old male after his second vaccine dose, with no further data beyond myocarditis, headache and fever.

Figure 2 shows the reporting rate of myocarditis and pericarditis in these two datasets. The rate in the reporting EU/EEA countries was 27.9 and 9.2 cases respectively of myocarditis and pericarditis per million vaccines administered.²¹ For the USA, the reporting rate was 16.2 and 4.8 cases per million of SARS-CoV-2 respectively.¹⁵ A higher percentage of male adolescents than females reported cardiac adverse effects for both conditions studied (myocarditis: 86.6% (EU/EEA)²¹ and 88.7% (USA)²⁰; pericarditis: 72.3% (EU/EEA)²¹ and 85.8% (USA)²⁰) (Table 3).

Only the USA VAERS provided data on the relationship of adverse events to vaccine dose; the rate of myocarditis per million after first dose was 12.4 for boys and 1.4 for girls, and 49.6 for boys and 6.1 for girls after the second dose. The reporting rate of pericarditis followed a similar trend. Across both sexes, the majority of cardiac events were reported after the second dose (myocarditis: 77.1%; pericarditis: 75.0%).

Again, only VAERS provided data on time to onset of symptoms and duration of hospitalisation. Median onset of symptoms was two days (range: 0 to > 120 days) after immunisation²⁰. The median days that CYP were hospitalised was two (ranging from no need of hospitalisation to two months)²⁰.

VAERS data for myocarditis and pericarditis events by month of vaccination are shown in Figure 3. For myocarditis, these show a trend for events after first and second doses to be higher soon after initiation of that element of the vaccine schedule (February 2021 for first dose, April 2021 for second doses). Incidence of events after second dose fell each month from July onwards, a pattern also seen in females. In the most recent months (September-October 2021), incidence of myocarditis after first doses was 7.6-12.3 in males and 0 in females, and after second dose 13.1-31.1 for males and 1.3-2.5 per million for females.

Incidence of pericarditis after the second dose in males appeared to follow a similar trend, being highest in February and April 2021 and falling thereafter. Incidence in the most recent two months was 2.6-4.1 per million for males and 0-1.3 for females.

Discussion

Our systematic review provides a comprehensive and up-to-date (November 2021) synthesis of reported data on cardiac adverse effects in CYP < 18 years after SARS-CoV-2 immunisation. Detailed clinical data were available on 127 cases across 17 studies, active surveillance data on 30 confirmed cases, and passive surveillance data on 1129 reports of myocarditis and 358 reports of pericarditis from across the USA and EU/EEA. It is highly likely that some or all of the clinical cases and active surveillance cases were contained within the passive surveillance reports. Events were also reported through the WHO VigiBase database, although the degree to which these events overlapped with the US and EU/EEA reports is unclear as these countries make up around 70% of VigiBase reports.

Clinical data were highly consistent across the three sources of data. The majority of cases occurred in males aged 15-17 years old who presented with chest pain, elevated serum troponin and C-reactive protein and an abnormal ECG with ST elevation. Fewer presented under age 15 years. We identified no cases under 12 years of age although very few doses have been given in this age group. Most presented with chest pain around 2 days after vaccination, predominantly their second dose. Almost all had high troponin levels, 73.8% had an abnormal ECG with variable echocardiography findings. Approximately 85% were hospitalised for short periods, with the great majority discharged within 2-7 days without treatment other than non-steroidal anti-inflammatory drugs. While longer-term data were only available on 16 young people from the VSD study, few remained on medication at 3 months. The clinical picture of myocarditis post-COVID-19 vaccination amongst 12-17 year olds was broadly similar to that previously reported across all ages.^{11 12}

There were no deaths in the clinical series nor in the active surveillance series, and none in the clinical series required significant cardiovascular or respiratory support. There were two male deaths reported in the passive surveillance data, although a causal link cannot be attributed to vaccination, given that all deaths within a 21 day period after vaccination maybe reported regardless of causation. It is important to note that in 2019 in the USA there were approximately 12 deaths males aged 12-17 years each day, with approximately 250 occurring in the average 21 day period, from a range of traumatic and medical causes.⁴⁸ Given that over 40% of 12-17 year olds in the USA have had at least one dose,²⁶ this suggests that there are likely to be a considerable number of deaths of adolescent boys soon after vaccination for reasons entirely unconnected with vaccination. Broader analysis of VAERS reports of deaths from myocarditis associated with COVID-19 vaccination across a broader age-group is reassuring that almost all reported cases are not vaccination-related. As of early November, 8 deaths were identified in those aged <30 years with possible concern for myocarditis after approximately 86 million vaccine doses; 3 were assessed as not being myocarditis, 3 as due to infectious (i.e. non-vaccine) myocarditis whilst evaluation was ongoing in 2 cases.⁴⁷

Data from active surveillance suggest a significant excess of confirmed myo- or pericarditis events in the 21 days post-vaccination compared with matched adolescents 22-42 days after vaccination, supporting a causal link for myocarditis with the Pfizer-BioNTech vaccine although numbers of events were low in this age-group. Passive surveillance data from VAERS and EudraVigilance provide an estimate of the reporting rate for unconfirmed events and cannot infer causality. These differences in data quality and estimation methods means that estimates are not directly comparable across the datasets, although estimates were broadly similar. Overall estimates across both sexes and both doses across the period were approximately 30 per million for myo-pericarditis for VSD and 17 and 28 per million for myocarditis in VAERS and EudraVigilance respectively. Estimates for events post first dose were approximately 4 per million from VSD and 1.4 and 12.4 for females and males respectively in VAERS.

However the time trends we identified in VAERS data for males suggest that the summary estimates across the study period are highly likely to be biased upwards. Estimates were higher amongst males after the second dose across the study period, however the monthly crude estimate decreased notably in the most recent 3 months. Whilst the most recent month may be lower due to incomplete reporting, previous studies showing higher levels of reporting in VAERS following publicity relating to claimed adverse events,⁴⁹ suggest that lower estimates from August and September 2021 (31.1-39.7 per million second doses) may be less biased, although trends may be continuing. It is unclear whether similar trends have occurred in notifications to EudraVigilance as trend data are not publicly available. Whilst there was no similar trend for events post first dose, it is notable that passive surveillance reports from the UK, which began vaccinating healthy adolescents from September 2021, more recently than the USA or many EU countries, identified a reporting rate of 0.8 events per million amongst 0-17 year olds after approximately 2.8 million doses of the Pfizer-BioNTech vaccine, the great majority being first doses.⁵⁰

Post-vaccination myocarditis must be seen in the context of myocarditis related to SARS-CoV-2 infection, post-COVID syndromes and other causes of myocarditis. A large Israeli study found the risk of vaccine-related myocarditis was found to be approximately 4-fold less than the risk of myocarditis due to SARS-CoV-2 infection across age-groups,⁹ although similar data are not available for the adolescent age-range. The post-COVID-19 Paediatric Inflammatory Multisystem Syndrome (PIMS) has well described cardiovascular involvement. Paediatric patients may present with cardiogenic shock, ECG abnormalities, myocardial dysfunction and coronary artery dilation¹⁰, with 71-75% patients being admitted to Paediatric Intensive Care Unit (PICU)^{51 52} although the risk of death is very low.⁵³ Further, the clinical picture and outcomes of myocarditis post-COVID-19 vaccination appear quite different to established causes of acute myocarditis in CYP, which occurs in around 8 per million CYP⁵⁴ and has a higher incidence of left ventricular dysfunction and arrhythmia, median length of stay 6-7 days,^{54 55} and mortality of up to 3-8%.^{54 56 57}

Other vaccines have rarely been linked with cardiac adverse effects.^{58 59 60} A reviewed of VAERS reports of myopericarditis after vaccination between 1990 and 2018 found 99 reports of myopericarditis in CYP, with most cases reported after *Haemophilus influenza* type b (22, 22%) and hepatitis B (18, 18%) vaccination⁶⁰. Most cases reported were in males (55,

56%), of high severity (40, 40%), and resulted in death in 55% of cases,⁶⁰ although this may reflect biased reporting only of severe cases.

Limitations

Our findings are subject to a number of limitations inherent in systematic reviews and in the data sources used. Publication bias towards greater severity is likely amongst the cases reported in the 17 case study/series studies, which may not be representative of the less severe cases.

Estimates from vaccine passive surveillance systems such as VAERS and EudraVigilance provide a reporting rate rather than an estimate of excess events, and are crude indicators of risks related to vaccines.⁶¹ They cannot attribute causality between vaccine and reported event, lack a comparison group, data quality is highly variable and they are open to a series of biases from over- and -under-reporting.⁶² VAERS in particular has been criticised as open to over-reporting by those opposed to COVID-19 vaccination.^{63 64} However all reports are regularly scrutinized to remove duplicate and reports identified as fraudulent,⁶² although the extent and timeliness of this is unclear. Passive surveillance systems are most useful for identifying potential safety signals that require further investigation⁶² through more detailed smaller studies using active systems such as the Vaccine Safety Datalink (VSD). The VSD data included here provide an estimate of excess events, but the VSD can lack power to examine small risks in specific populations²⁵ such as the CYP studied here.

Our data focus on 12-17 year olds and should not be regarded as informative for younger children, as very few received COVID-19 vaccination during the period of study here. We were unable to include data from some large all-age studies¹² as these did not provide data specifically for those <18y. We were unable to further breakdown VAERS data by age within the adolescent range; a CDC report from October 2021 reported that pooled risk for 16-17 year olds was higher after the second dose (69.1 per million) than amongst 12-15 year olds (39.9 per million).⁴⁷ We estimated sex-specific reporting rates from VAERS data using proportional differences in vaccine uptake in US adolescents. We were unable to compare risk of cardiac events after the Pfizer-BioNTech and Moderna vaccines in this age group due to lack of data. We were further unable to comment on risk of myocarditis after third doses due to lack of data as no country has introduced booster doses for this age-group.

Conclusions

Cardiac adverse effects are very rare after use of mRNA vaccination for COVID-19 in CYP <18 years. The great majority of cases are mild and self-limiting without significant treatment, in contrast to viral myocarditis. No data are yet available on children under 12 years and these are awaited as vaccination of 5 to 11 year olds is rolled-out in some countries. Larger detailed prospective longitudinal studies from active surveillance sources on both children and adolescents are urgently needed to better understand the frequency and natural history of the condition.

424

425 Funding

426 JC, SEK and RMV are in receipt of a grant from the National Institute of Health Research to
427 support this work (grant number NIHR202322). LKF is funded by a National Institute for
428 Health Research (NIHR) Career Development Fellowship (award CDF-2018-11-ST2-002).

429 Funders had no role in the design, data collection, analysis, decision to publish, or prepara-
430 tion of the manuscript.

431

References

1. Evans SJW, Jewell NP. Vaccine Effectiveness Studies in the Field. *N Engl J Med* 2021;385(7):650-51. doi: 10.1056/NEJMe2110605 [published Online First: 2021/07/22]
2. Diaz GA, Parsons GT, Gering SK, et al. Myocarditis and Pericarditis After Vaccination for COVID-19. *JAMA* 2021;326(12):1210-12. doi: 10.1001/jama.2021.13443 [published Online First: 2021/08/05]
3. Simone A, Herald J, Chen A, et al. Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. *JAMA Intern Med* 2021 doi: 10.1001/jamainternmed.2021.5511 [published Online First: 2021/10/05]
4. European Medicines Agency (EMA). COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU European Medicines Agency (EMA)2021 [Available from: <https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approved-children-aged-12-17-eu> accessed 05/10/2021 2021.
5. US Food & Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine: US FDA; 2021 [Available from: <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine> accessed 05/10/2021 2021.
6. Vogel G, Couzin-Frankel J. Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. *Science* 2021;10
7. Ojha V, Verma M, Pandey NN, et al. Cardiac Magnetic Resonance Imaging in Coronavirus Disease 2019 (COVID-19): A Systematic Review of Cardiac Magnetic Resonance Imaging Findings in 199 Patients. *J Thorac Imaging* 2021;36(2):73-83. doi: 10.1097/rti.0000000000000574 [published Online First: 2020/12/12]
8. Boehmer TK, Kompaniyets L, Lavery AM, et al. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data - United States, March 2020-January 2021. *MMWR Morb Mortal Wkly Rep* 2021;70(35):1228-32. doi: 10.15585/mmwr.mm7035e5 [published Online First: 2021/09/03]
9. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *N Engl J Med* 2021;385(12):1078-90. doi: 10.1056/NEJMoa2110475 [published Online First: 2021/08/26]
10. Alsaied T, Tremoulet AH, Burns JC, et al. Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children. *Circulation* 2021;143(1):78-88. doi: 10.1161/circulationaha.120.049836 [published Online First: 2020/11/10]
11. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. *N Engl J Med* 2021 doi: 10.1056/NEJMoa2110737 [published Online First: 2021/10/07]
12. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. *N Engl J Med* 2021 doi: 10.1056/NEJMoa2109730 [published Online First: 2021/10/07]
13. Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. *Mmwr-Morbidity and Mortality Weekly Report* 2021;70(27):977-82.
14. Su JR. Myopericarditis following COVID-19 vaccination: Updates from the Vaccine Adverse Event Reporting System (VAERS) CDC COVID-19 Vaccine Task Force, 2021.

15. Centers for Disease Control and Prevention. COVID-19 Vaccination Demographics in the United States, National 15/09/2021 ed. CDC, 2021.
16. European Centre for Disease Prevention and Control (ECDC). COVID-19 Vaccine Tracker. Stockholm: ECDC, 2021.
17. Coronavirus vaccine - weekly summary of Yellow Card reporting: updated 19 November 2021: Medicines and Healthcare products Regulatory Agency (MHRA), 2021.
18. COVID-19 vaccination – vaccination data – 1 November 2021: Australian Government - Department of Health, 2021.
19. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLOS Medicine* 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097
20. Centers for Disease Control and Prevention. The Vaccine Adverse Event Reporting System (VAERS) results. September 3, 2021. VAERS, 2021.
21. European Medicines Agency (EMA). Eudravigilance - European database of suspected adverse drug reaction reports, 2021.
22. Riley DS, Barber MS, Kienle GS, et al. CARE guidelines for case reports: explanation and elaboration document. *J Clin Epidemiol* 2017;89:218-35. doi: <https://doi.org/10.1016/j.jclinepi.2017.04.026>
23. Chouchana L, Blet A, Al-Khalaf M, et al. Cardiac Inflammation after COVID-19 mRNA Vaccines: A Global Pharmacovigilance Analysis. *medRxiv* 2021:2021.08.12.21261955. doi: 10.1101/2021.08.12.21261955
24. World Health Organisation (WHO). VigiAccess. Comirnaty: WHO, 2021.
25. Baggs J, Gee J, Lewis E, et al. The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety. *Pediatrics* 2011;127(Supplement_1):S45-S53. doi: 10.1542/peds.2010-1722H
26. Murthy BP, Zell E, Saelee R, et al. COVID-19 Vaccination Coverage Among Adolescents Aged 12-17 Years - United States, December 14, 2020-July 31, 2021. *Mmwr-Morbidity and Mortality Weekly Report* 2021;70(35):1206-13.
27. Abu Mouch S, Roguin A, Hellou E, et al. Myocarditis following COVID-19 mRNA vaccination. *Vaccine* 2021;39(29):3790-93. doi: 10.1016/j.vaccine.2021.05.087 [published Online First: 2021/06/08]
28. Das BB, Kohli U, Ramachandran P, et al. Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. *J Pediatr* 2021;238:26-32. doi: <https://doi.org/10.1016/j.jpeds.2021.07.044> [published Online First: 2021/08/03]
29. Dionne A, Sperotto F, Chamberlain S, et al. Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. *JAMA Cardiol* 2021 doi: 10.1001/jamacardio.2021.3471 [published Online First: 2021/08/11]
30. Fleming-Nouri A, Haimovich AD, Yang D, et al. Myopericarditis in young adults presenting to the emergency department after receiving a second COVID-19 mRNA vaccine. *Acad Emerg Med* 2021;28(7):802-05. doi: 10.1111/acem.14307 [published Online First: 2021/07/27]
31. Isaak A, Feisst A, Luetkens JA. Myocarditis Following COVID-19 Vaccination. *Radiology* 2021;301(1):E378-E79. doi: 10.1148/radiol.2021211766 [published Online First: 2021/08/04]

32. Jain SS, Steele JM, Fonseca B, et al. COVID-19 Vaccination-Associated Myocarditis in Adolescents. *Pediatrics* 2021;148(5) doi: 10.1542/peds.2021-053427 [published Online First: 2021/08/15]
33. Marshall M, Ferguson ID, Lewis P, et al. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. *Pediatrics* 2021;148(3) doi: 10.1542/peds.2021-052478 [published Online First: 2021/06/06]
34. McLean K, Johnson TJ. Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report. *Acad Emerg Med* 2021;28(8):918-21. doi: 10.1111/acem.14322 [published Online First: 2021/06/17]
35. Minocha PK, Better D, Singh RK, et al. Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. *J Pediatr* 2021;238:321-23. doi: 10.1016/j.jpeds.2021.06.035 [published Online First: 2021/06/25]
36. Park J, Brekke DR, Bratincsak A. Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. *Cardiol Young* 2021:1-4. doi: 10.1017/S1047951121002547 [published Online First: 2021/06/29]
37. Schauer J, Buddhe S, Colyer J, et al. Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. *J Pediatr* 2021;238:317-20. doi: 10.1016/j.jpeds.2021.06.083 [published Online First: 2021/07/07]
38. Shaw KE, Cavalcante JL, Han BK, et al. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings. *JACC Cardiovasc Imaging* 2021;14(9):1856-61. doi: 10.1016/j.jcmg.2021.06.002 [published Online First: 2021/07/12]
39. Snapiri O, Rosenberg Danziger C, Shirman N, et al. Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. *Pediatr Infect Dis J* 2021;40(10):e360-e63. doi: 10.1097/INF.0000000000003235 [published Online First: 2021/06/03]
40. Starekova J, Bluemke DA, Bradham WS, et al. Myocarditis Associated with mRNA COVID-19 Vaccination. *Radiology* 2021;301(2):E409-E11. doi: 10.1148/radiol.2021211430 [published Online First: 2021/07/21]
41. Tano E, San Martin S, Girgis S, et al. Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine. *J Pediatric Infect Dis Soc* 2021;10(10):962-66. doi: 10.1093/jpids/piab060 [published Online First: 2021/07/29]
42. Patel T, Kelleman M, West Z, et al. Comparison of MIS-C Related Myocarditis, Classic Viral Myocarditis, and COVID-19 Vaccine related Myocarditis in Children. *medRxiv* 2021:2021.10.05.21264581. doi: 10.1101/2021.10.05.21264581
43. Ambati S, Colon M, Mihic M, et al. Acute Myopericarditis after COVID-19 Vaccine in Teenagers. *Case Rep Cardiol* 2021;2021:8268755. doi: 10.1155/2021/8268755 [published Online First: 2021/10/01]
44. Lane S, Yeomans A, Shakir S. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccines: A review of spontaneously reported data from the UK, Europe, and the US. *medRxiv* 2021:2021.09.09.21263342. doi: 10.1101/2021.09.09.21263342
45. Klein NP. Rapid Cycle Analysis to Monitor the Safety of COVID-19 Vaccines in Near Real-Time within the Vaccine Safety Datalink: Myocarditis and Anaphylaxis: Centers for Disease Control, 2021.

46. Klein NP. Myocarditis Analyses in the Vaccine Safety Datalink: Rapid Cycle Analyses and “Head-to-Head” Product Comparisons: Centres for Disease Control, 2021.
47. Oster M. mRNA COVID-19 Vaccine-Associated Myocarditis: Centres for Disease Control, 2021.
48. United States Department of Health and Human Services (US DHHS), Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). Underlying Cause of Death 1999-2019 on CDC WONDER Online Database, released 2020. In: United States Department of Health and Human Services (US DHHS) CfDcCaPC, National Center for Health Statistics (NCHS), ed.: Centers for Disease Control and Prevention (CDC), 2021.
49. Motta M, Stecula D. Quantifying the effect of Wakefield et al. (1998) on skepticism about MMR vaccine safety in the U.S. *PloS one* 2021;16(8):e0256395. doi: 10.1371/journal.pone.0256395 [published Online First: 20210819]
50. Story MT, Neumark-Stzainer DR, Sherwood NE, et al. Management of child and adolescent obesity: attitudes, barriers, skills, and training needs among health care professionals. *Pediatrics* 2002;110(1 Pt 2):210-14.
51. Henrina J, Putra ICS, Lawrensia S, et al. Cardiac Manifestations, Treatment Characteristics, and Outcomes of Paediatric Inflammatory Multisystem Syndrome Temporally Associated with Severe Acute Respiratory Syndrome Coronavirus-2: systematic review of case reports and case series. *Prog Pediatr Cardiol* 2021:101365. doi: 10.1016/j.ppedcard.2021.101365 [published Online First: 2021/02/16]
52. Rodriguez-Gonzalez M, Castellano-Martinez A, Cascales-Poyatos HM, et al. Cardiovascular impact of COVID-19 with a focus on children: A systematic review. *World J Clin Cases* 2020;8(21):5250-83. doi: 10.12998/wjcc.v8.i21.5250 [published Online First: 2020/12/04]
53. Smith C, Odd D, Harwood R, et al. Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. *Nat Med* 2021 doi: 10.1038/s41591-021-01578-1 [published Online First: 20211111]
54. Vasudeva R, Bhatt P, Lilje C, et al. Trends in Acute Myocarditis Related Pediatric Hospitalizations in the United States, 2007-2016. *Am J Cardiol* 2021;149:95-102. doi: 10.1016/j.amjcard.2021.03.019 [published Online First: 2021/03/25]
55. Lota A, Fazal S, Wassall R, et al. National Trends in the Epidemiology of Hospital Admissions for Acute Myocarditis: Insights from the Uk National Health Service. *Journal of the American College of Cardiology* 2018;71(11):A875-A75. doi: 10.1016/s0735-1097(18)31416-5
56. Wu MH, Wu ET, Wang CC, et al. Contemporary Postnatal Incidence of Acquiring Acute Myocarditis by Age 15 Years and the Outcomes From a Nationwide Birth Cohort. *Pediatr Crit Care Med* 2017;18(12):1153-58. doi: 10.1097/PCC.0000000000001363 [published Online First: 2017/10/27]
57. Chou FS, Ghimire LV. Identification of prognostic factors for pediatric myocarditis with a random forests algorithm-assisted approach. *Pediatr Res* 2021;90(2):427-30. doi: 10.1038/s41390-020-01268-7 [published Online First: 2020/11/20]
58. Engler RJ, Nelson MR, Collins LC, Jr., et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. *PLoS One* 2015;10(3):e0118283. doi: 10.1371/journal.pone.0118283 [published Online First: 2015/03/21]

59. Kuntz J, Crane B, Weinmann S, et al. Myocarditis and pericarditis are rare following live viral vaccinations in adults. *Vaccine* 2018;36(12):1524-27. doi: 10.1016/j.vaccine.2018.02.030 [published Online First: 2018/02/20]
60. Su JR, McNeil MM, Welsh KJ, et al. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018. *Vaccine* 2021;39(5):839-45. doi: 10.1016/j.vaccine.2020.12.046 [published Online First: 2021/01/11]
61. Johns Hopkins Bloomberg School of Public Health. Clinical presentation & Prognostic risk factors, vaccines: SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis 2021 [Available from: <https://ncrc.jhsph.edu/research/sars-cov-2-mrna-vaccination-associated-myocarditis-in-children-ages-12-17-a-stratified-national-database-analysis/> accessed 06/10/2021.
62. Shimabukuro TT, Nguyen M, Martin D, et al. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). *Vaccine* 2015;33(36):4398-405. doi: 10.1016/j.vaccine.2015.07.035 [published Online First: 2015/07/22]
63. Munro C. Covid-19: Boys are more at risk of myocarditis after vaccination than of hospital admission for covid. *BMJ* 2021;374:n2251. doi: 10.1136/bmj.n2251 [published Online First: 2021/09/16]
64. English C. FDA-Approved Shots Dangerous? VAERS Database Continues To Make Vaccine Skeptics Look Foolish: American Council on Science and Health; 2021 [updated 4 June 2021;18 November 2021]. Available from: <https://www.acsh.org/news/2021/06/04/fda-approved-shots-dangerous-vaers-database-continues-make-vaccine-skeptics-look-foolish-15583>.

640 Figure 1. PRISMA search flowchart

641

642 **Table 1** - Characteristics and outcomes of the studies describing patients with cardiac adverse effects (myocarditis, pericarditis or myopericarditis
643 related to COVID-19 vaccination.

Study	Type of study	Number of cases	Case source	Male sex (%)	Age, years (range)	Vaccine type	% Patients presenting after second vaccination	Time between last vaccine and symptom onset, median days (range)	% Patients with symptoms resolved	Median hospitalisation, days (range)
³¹	Case report	1	Single centre, Germany	100	16	BNT 162b2 (Pfizer)	100	1	NR	7
McLean and Johnson ³⁴	Case report	1	Single centre, USA	100	16	BNT 162b2 (Pfizer)	100	3	100	6
Minocha, et al. ³⁵	Case report	1	Single centre, USA	100	17	BNT 162b2 (Pfizer)	100	2	100	6
Starekova, et al. ⁴⁰	Case report	1	Single centre, USA	100	17	BNT 162b2 (Pfizer)	100	2	NR	NR
Abu Mouch, et al. ²⁷	Case report	2	Single centre, Israel	100	16.5 (16-17)	BNT 162b2 (Pfizer)	100	2 (1-3)	100	6 (5-7)
Fleming-Nouri, et al. ³⁰	Case report	2	Single centre, USA	100	16.5 (16-17)	BNT 162b2 (Pfizer)	100	4.5 (2-7)	NR	3 (2-4)
Park, et al. ³⁶	Case report	2	Single centre, USA	100	15.5 (15-16)	BNT 162b2 (Pfizer)	50	2.5 (2-3)	100	4
Shaw, et al. ³⁸	Case report	2	Multiple centres, USA	50	17 (16-17)	BNT 162b2 (Pfizer)	50	3 (2-4)	NR	NR
Ambati, et al. ⁴³	Case report	2	Single centre, USA	100	17 (16-17)	BNT 162b2 (Pfizer)	100	2.5 (2-3)	100	3
Marshall, et al. ³³	Case report	5	Multiple centres, USA	100	16 (14-17)	BNT 162b2 (Pfizer)	100	2 (2-3)	NR	3.5 (2-5)

Snapiri, et al. ³⁹	Case report	7	Multiple centres, Israel	100	16 (16-17)	BNT 162b2 (Pfizer)	86	2 (1-3)	NR	5 (3-6)
Tano, et al. ⁴¹	Case report	8	Single centre, USA	100	16 (15-17)	BNT 162b2 (Pfizer)	75	3 (1-14)	NR	2.5 (1-4)
Patel, et al. ⁴²	Case series	9	Single centre, USA	100	15.7 (IQR: 14.5; 16.6)	Not identified	89	3	100	NR
Schauer, et al. ³⁷	Case report	13	Single centre, USA	92	15 (12-17)	BNT 162b2 (Pfizer)	100*	3 (2-4)	100	2 (1-4)
Dionne, et al. ²⁹	Case series	15	Single centre, USA	93	15 (12-18)	BNT 162b2 (Pfizer)	93	3 (1-6)	73	2 (1-5)
Das, et al. ²⁸	Case series	25	Multiple centres, USA	88	15 (12-17)	BNT 162b2 (Pfizer)	88	2 (<1-20)	100	3 (1-7)
Jain, et al. ³²	Case series	31	Multiple centres, USA	87	12-15. Note that an additional 32 cases aged 16-20y were not included here	BNT 162b2 (Pfizer) mRNA-1273 (Moderna)	97	1.9 (1-3)	NR	2.8 (1-5)

644

645 NR – Not Reported

646 *The authors only considered patients presenting myocarditis after the 2nd dose of the vaccine

647 **Table 2** - Summary of the most common symptoms presented by patients diagnosed with car-
648 *diac adverse effects after being vaccinated against SARS-CoV-2*
649

	N	Number of patients (%)
Symptoms at hospital admission	127	
Chest pain	127	126 (99.2)
Fever	127	44 (34.6)
Shortness of breath	127	26 (20.5)
Weakness	127	22 (17.3)
Headache	127	21 (16.5)
Myalgia	127	18 (14.2)
Nausea	127	11 (8.7)
Vomiting	127	5 (3.9)
Chills	127	5 (3.9)
Tachycardia	127	4 (3.1)
Diaphoresis	127	1 (0.8)
Syncope	127	1 (0.8)
Tingling of fingers	127	1 (0.8)
Laboratory analysis		
Elevated Troponin	127	127 (100)
Elevated C-Reactive Protein	95	92 (96.8)
Electrocardiogram (ECG)	126	
Abnormal	126	93 (73.8)
Diffuse ST changes	126	21 (16.7)
ST segment elevation	126	55 (43.7)
T-wave inversion	126	8 (6.3)
Echocardiogram (Echo)	124	
Systolic or diastolic dysfunction	124	7 (5.6)
Pericardial effusion	124	14 (11.3)
Cardiovascular magnetic resonance (CMR)	91	
Systolic or diastolic dysfunction	91	7 (7.7)
Increased wall thickness	91	2 (2.2)
Pericardial effusion	91	19 (20.9)
Myocardial oedema	91	56 (61.5)
Late gadolinium enhancement (LGE)	91	82 (90.1)
Treatment	121	
NSAID	121	92 (76.0)

IVIG	121	24 (19.8)
Steroid	121	18 (14.9)
Colchicine	121	3 (2.5)
Famotidine	121	3 (2.5)
Aspirin (low dose)	121	2 (1.7)
Enalapril	121	2 (1.7)
Spirolactone	121	2 (1.7)
Furosemide	121	2 (1.7)
Vasopressor	121	2 (1.7)
Narcotic	121	1 (0.8)
No treatment required	121	2 (1.7)

651 Table 3. Updated data on SARS-CoV-2 vaccination cardiac adverse effects (CAE) (myocarditis and pericarditis) from VAERS and EudraVigilance for
652 children and young people aged between 6 and 17 years old (VAERS) and 3 and 17 years old (EudraVigilance).

653

Region		Both sexes			Males			Females			Vaccination date (up to)	Reported CAE date (up to)
		Dose 1	Dose 2	Total	Dose 1	Dose 2	Total	Dose 1	Dose 2	Total		
USA											31/10/2021	31/10/2021
	Number of vaccinations	13,634,026	11,475,125	25,109,151	6,683,248	5,585,905	12,269,153	6,950,778	5,889,220	12,839,998		
	Myocarditis (N)	93	313	406	83	277	360	10	36	46		
	Pericarditis (N)	30	90	120	22	81	103	8	9	17		
EU/EEA											06/11/2021	13/11/2021
	Number of vaccinations	13,925,558	12,004,598	25,930,156								
	Myocarditis (N)	NA	NA	723	NA	NA	626	NA	NA	97		
	Pericarditis (N)	NA	NA	238	NA	NA	172	NA	NA	66		

654

655

656 NA – no data available stratified by dose administered.

657 Figure 2 – Number of cases of myocarditis and pericarditis reported per 1,000,000 of SARS-
658 CoV-2 vaccines administered to children and adolescents (≤ 17 years old) reported to Eudra-
659 Vigilance (EU/EEA) and Vaccine Adverse Event Reporting System (VAERS) (USA).
660

661

662

663 *Figure 3. Crude incidence of cases of myocarditis and pericarditis reported to the Vaccine Adverse Event Reporting System (VAERS) per million*
664 *vaccines, by month of vaccination*